Cargando…
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
BACKGROUND AND AIMS: Individualization of treatment with peginterferon alfa and ribavirin in patients with chronic hepatitis C showed benefit in controlled trials and was implemented in treatment guidelines to increase response rates and to reduce side effects and costs. However, it is unknown wheth...
Autores principales: | Hofmann, Wolf Peter, Mauss, Stefan, Lutz, Thomas, Schober, Andreas, Böker, Klaus, Moog, Gero, Baumgarten, Axel, Pfeiffer-Vornkahl, Heike, Alshuth, Ulrich, Hüppe, Dietrich, Wedemeyer, Heiner, Manns, Michael P., Schott, Eckart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521757/ https://www.ncbi.nlm.nih.gov/pubmed/26230998 http://dx.doi.org/10.1371/journal.pone.0134839 |
Ejemplares similares
-
Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort
por: Baumgarten, A, et al.
Publicado: (2010) -
Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
por: Witthöft, Th, et al.
Publicado: (2007) -
Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005) -
Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3
por: Niederau, Claus, et al.
Publicado: (2014) -
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B
por: Marcellin, Patrick, et al.
Publicado: (2020)